Date:3/10/2011

y of Illinois at Chicago (1976-1977)(3). Dr. Kinghorn has specialized in work on antimicrobials, botanical dietary supplements, cancer chemopreventive agents, cancer chemotherapeutic agents, and noncariogenic sweeteners/sweetness modifiers(3-4). Since Dr. Kinghorn concluded his research on sweet compounds such as stevia glycosides a few years ago, he has researched the potential cancer chemopreventive principles and the biologically active principles of botanicals such as licorice (Glycyrrhiza spp.), mangosteen (Garcinia mangostana), noni (Morinda citrifolia), acai (Euterpe oleraceae), and baobab (Adansonia digitata). Dr. Kinghorn's research has been independently supported by the US National Institutes of Health (NIH) and by private industry since 1980(3). He currently serves as Principal Investigator of a collaborative multi-institutional program project award from the US National Cancer Institute in Maryland directed towards the discovery of naturally occurring anticancer agent(3)."It's obvious that Doug Kinghorn has contributed as much, if not more, than any medicinal plant scientist on the scene today related to the chemistry and pharmacology of many botanicals," said Dr. Farnsworth.  "I can think of only one or two other people that might come close. Also, his pioneering work with plant-derived sweeteners is extensive over a long period of time."

Dr. Kinghorn's vast contribution to botanical literature comprises six books — including his 2002 book on stevia, Stevia: The genus Stevia (Taylor and Francis, 2002) — and the more than 450 research articles, book chapters, and reviews he has written or co-authored(3). He has shared his extensive knowledge and research at seminars and scientific meetings in more than 30 different countries around the globe(3).Dr. Kinghorn is presently distinguished as Editor-in-Chief of the

SOURCE American Botanical Council Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
2. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
3. Amarin Announces Proposed Public Offering of American Depositary Shares
4. Argus Launches North American Wood Chip Price Assessments
5. Nobel Prize Winner Robert Edwards: A Personal Memoir by the Only American Physician to Participate in Developing IVF
6. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
7. New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
8. Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
9. Enerkem adds two new executive roles to growing North American presence
10. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
11. PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting